| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | -0.0047 | 0.9 |